Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants

Journal of Virology

Volumn 78, Issue 16, 2004, Pages 8524-8535

  Tacke, Frank ^a   Gehrke, Christina ^a   Luedde, Tom ^a   Heim, Albert ^a   Manns, Michael P ^a   Trautwein, Christian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; STOP CODON; VIRION; VIRUS CAPSID; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN; YMDD MOTIF;

CELL LINE, TUMOR; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 3543081472     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.16.8524-8535.2004     Document Type: Article

References (58)

1. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. E. Delaney, C. Gibbs, C. L. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
2. Baptista, M., A. Kramvis, and M. C. Kew. 1999. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29:946-953.
3. Bock, C. T., B. Buerke, H. L. Tillmann, F. Tacke, V. Kliem, M. P. Manns, and C. Trautwein. 2003. Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology 124:1809-1820.
4. Bock, C. T., H. L. Tillmann, H. J. Maschek, M. P. Manns, and C. Trautwein. 1997. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 113:1976-1982.
5. Bock, C. T., H. L. Tillmann, J. Torresi, J. Klempnauer, S. Locarnini, M. P. Manns, and C. Trautwein. 2002. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273.
6. Buckwold, V. E., Z. Xu, M. Chen, T. S. Yen, and J. H. Ou. 1996. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70:5845-5851.
7. Chan, H. L., M. Hussain, and A. S. Lok. 1999. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 29:976-984.
8. Chan, H. L., S. W. Tsang, C. T. Liew, C. H. Tse, M. L. Wong, J. Y. Ching, N. W. Leung, J. S. Tam, and J. J. Sung. 2002. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. 97:406-412.
9. Chen, R. Y., R. Edwards, T. Shaw, D. Colledge, W. E. Delaney, H. Isom, S. Bowden, P. Desmond, and S. A. Locarnini. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
10. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, H. Isom, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxotane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracit. Antimicrob. Agents Chemother. 45:2495-2501.
11. Chu, C. J., E. B. Keeffe, S. H. Han, R. P. Perrillo, A. D. Min, C. Soldevila-Pico, W. Carey, R. S. Brown, Jr., V. A. Luketic, N. Terrault, and A. S. Lok. 2003. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 125:444-451.
12. Chu, C. J., E. B. Keeffe, S. H. Han, R. P. Perrillo, A. D. Min, C. Soldevila-Pico, W. Carey, R. S. Brown, Jr., V. A. Luketic, N. Terrault, and A. S. Lok. 2003. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38:619-628.
13. Delaney, W. E., R. Edwards, D. Colledge, T. Shaw, J. Torresi, T. G. Miller, H. C. Isom, C. T. Bock, M. P. Manns, C. Trautwein, and S. Locarnini. 2001. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother. 45:1705-1713.
14. Delaney, W. E., S. Locarnini, and T. Shaw. 2001. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir. Chem. Chemother. 12:1-35.
15. EASL consensus statement. 2003. EASL International Consensus Conference on Hepatitis B, 13 to 14 September 2002, Geneva, Switzerland. Consensus statement (short version). J. Hepatol. 38:533-540.
16. Erhardt, A., U. Reineke, D. Blondin, W. H. Gerlich, O. Adams, T. Heintges, C. Niederau, and D. Haussinger. 2000. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31:716-725.
17. Fang, Z. L., J. Yang, X. Ge, H. Zhuang, J. Gong, R. Li, R. Ling, and T. J. Harrison. 2002. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J. Med. Virol. 68:33-40.
18. Funk, M. L., D. M. Rosenberg, and A. S. Lok. 2002. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 9:52-61.
19. Guidotti, L. G., B. Matzke, C. Pasquinelli, J. M. Shoenberger, C. E. Rogler, and F. V. Chisari. 1996. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J. Virol. 70:7056-7061.
20. Hadziyannis, S. J., G. V. Papatheodoridis, E. Dimou, A. Laras, and C. Papaioannou. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32:847-851.
21. Hadziyannis, S. J., G. V. Papatheodoridis, and D. Vassilopoulos. 2003. Treatment of HBeAg-negative chronic hepatitis B. Semin. Liver Dis. 23:81-88.
22. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
23. Hadziyannis, S. J., and D. Vassilopoulos. 2001. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624.
24. Honda, A., O. Yokosuka, T. Ehata, M. Tagawa, F. Imazeki, and H. Saisho. 1999. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status. J. Med. Virol. 57:337-344.
25. Honkoop, P., H. G. Niesters, R. A. de Man, A. D. Osterhaus, and S. W. Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26:1393-1395.
26. Hunt, C. M., J. M. McGill, M. I. Allen, and L. D. Condreay. 2000. Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037-1044.
27. Jeong, J. K., G. S. Yoon, and W. S. Ryu. 2000. Evidence that the 5′-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA. J. Virol. 74:5502-5508.
28. Jursch, C. A., W. H. Gerlich, D. Glebe, S. Schaefer, O. Marie, and O. Thraenhart. 2002. Molecular approaches to validate disinfectants against human hepatitis B virus. Med. Microbiol. Immunol. (Berlin) 190:189-197.
29. Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334.
30. Klein, C., C. T. Bock, H. Wedemeyer, T. Wüstefeld, S. A. Locarnini, H. P. Dienes, S. Kubicka, M. P. Manns, and C. Trautwein. 2003. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125:9-18.
31. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
32. Lamberts, C., M. Nassal, I. Velhagen, H. Zentgraf, and C. H. Schroder. 1993. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J. Virol. 67:3756-3762.
33. Laras, A., J. Koskinas, and S. J. Hadziyannis. 2002. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 295:86-96.
34. Lee, W. M. 1997. Hepatitis B virus infection. N. Engl. J. Med. 337:1733-1745.
35. Leung, N. W., C. L. Lai, T. T. Chang, R. Guan, C. M. Lee, K. Y. Ng, S. G. Lim, P. C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, and R. N. Chien. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
36. Li, J., V. E. Buckwold, M. W. Hon, and J. H. Ou. 1999. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J. Virol. 73:1239-1244.
37. Lindh, M., C. Hannoun, A. P. Dhillon, G. Norkrans, and P. Horal. 1999. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J. Infect. Dis. 179:775-782.
38. Locarnini, S., J. MeMillan, and A. Bartholomeusz. 2003. The hepatitis B virus and common mutants. Semin. Liver Dis. 23:5-20.
39. Lok, A. S., U. Akarca, and S. Greene. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc. Natl. Acad. Sci. USA 91:4077-4081.
40. Lok, A. S., M. Hussain, C. Cursano, M. Margotti, A. Gramenzi, G. L. Grazi, E. Jovine, M. Benardi, and P. Andreone. 2000. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32:1145-1153.
41. Manesis, E. K., and S. J. Hadziyannis. 2001. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121:101-109.
42. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
43. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
44. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449-455.
45. Ono-Nita, S. K., N. Kato, Y. Shiratori, K. H. Lan, H. Yoshida, F. J. Carrilho, and M. Omata. 1999. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J. Clin. Investig. 103:1635-1640.
46. Ono-Nita, S. K., N. Kato, Y. Shiratori, T. Masaki, K. H. Lan, F. J. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
47. Papatheodoridis, G. V., E. Dimou, A. Laras, V. Papadimitropoulos, and S. J. Hadziyannis. 2002. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36:219-226.
48. Parekh, S., F. Zoulim, S. H. Ahn, A. Tsai, J. Li, S. Kawai, N. Khan, C. Trepo, J. Wands, and S. Tong. 2003. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J. Virol. 77:6601-6612.
49. Perrillo, R., E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, K. Gutfreund, P. Lamy, and A. Murray. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
50. Pollack, J. R., and D. Ganem. 1993. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol. 67:3254-3263.
51. Rodriguez-Frias, F., M. Buti, R. Jardi, M. Cotrina, L. Viladomiu, R. Esteban, and J. Guardia. 1995. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 22:1641-1647.
52. Scaglioni, P. P., M. Melegari, and J. R. Wands. 1997. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and pre-core open reading frame. Virology 233:374-381.
53. Scaglioni, P. P., M. Melegari, and J. R. Wands. 1997. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J. Virol. 71:345-353.
54. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
55. Tacke, F., C. Trautwein, S. Zhao, M. Andreeff, M. P. Manns, A. Ganser, and P. Schöffski. 2002. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver 22:205-212.
56. Tassopoulos, N. C., R. Volpes, G. Pastore, J. Heathcote, M. Buti, R. D. Goldin, S. Hawley, J. Barber, L. Condreay, D. F. Gray, et al. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
57. Tong, S. P., C. Diot, P. Gripon, J. Li, L. Vitvitski, C. Trepo, and C. Guguen-Guillouzo. 1991. In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology 181:733-737.
58. Yotsuyanagi, H., K. Hino, E. Tomita, J. Toyoda, K. Yasuda, and S. Iino. 2002. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J. Hepatol. 37:355-363.